Table 1. Demographic and Baseline Information by Treatment and History of MI or Stroke vs No MI or Strokea.
| Characteristic | Patients with prior MI or stroke (n = 1455) | Patients without prior MI or stroke (n = 12 068) | ||
|---|---|---|---|---|
| CTD (n = 733) | HCTZ (n = 722) | CTD (n = 6023) | HCTZ (n = 6045) | |
| Age, median (IQR), y | 72 (69-75) | 72 (69-76) | 71 (69-75) | 71 (69-75) |
| Sex | ||||
| Female | 17 (2.3) | 14 (1.9) | 203 (3.4) | 197 (3.3) |
| Male | 716 (97.7) | 708 (98.1) | 5820 (96.6) | 5848 (96.7) |
| Race | ||||
| Black or African American | 151 (20.6) | 135 (18.7) | 853 (14.2) | 888 (14.7) |
| White | 523 (71.4) | 538 (74.5) | 4706 (78.1) | 4687 (77.5) |
| Otherb | 18 (1.2) | 19 (2.6) | 148 (2.5) | 139 (2.3) |
| Unknown due to missing data | 41 (5.6) | 30 (4.2) | 316 (5.3) | 331 (5.5) |
| Ethnicity | ||||
| Hispanic or Latino | 26 (3.5) | 30 (4.2) | 211 (3.5) | 227 (3.8) |
| Not Hispanic or Latino | 680 (92.8) | 672 (93.1) | 5601 (93.0) | 5596 (92.6) |
| Resided in rural areac | 306 (41.8) | 309 (42.8) | 2737 (45.4) | 2770 (45.8) |
| BMI, median (IQR) | 30 (27-34) | 30 (27-34) | 31 (28-35) | 31 (28-35) |
| Medical history | ||||
| Diabetes | 396 (54.0) | 387 (53.6) | 2571 (42.7) | 2675 (44.3) |
| Heart failure | 109 (14.9) | 132 (18.3) | 416 (6.9) | 394 (6.5) |
| MI | 230 (31.4) | 258 (35.7) | NA | NA |
| Stroke | 534 (72.9) | 495 (68.6) | NA | NA |
| eGFR <60 mL/min/1.73m2 | 213 (30.8) | 214 (31.0) | 1337 (23.5) | 1333 (23.4) |
| Current smoker | 223 (32.2) | 198 (29.4) | 1297 (23.0) | 1239 (22.0) |
| Systolic BP, median (IQR), mm Hg | 136 (130-146) | 137 (129-149) | 136 (129-146) | 136 (129-146) |
| Antihypertensive drugs used, median (IQR), No. | 3 (2-4) | 3 (2-4) | 3 (2-3) | 3 (2-3) |
| Hydrochlorothiazide used | ||||
| Received HCTZ, 25 mg | 685 (93.5) | 693 (96.0) | 5694 (94.5) | 5709 (94.4) |
| Alone | 59 (8.1) | 42 (5.8) | 830 (13.8) | 824 (13.6) |
| Plus 1 BP medication | 191 (26.1) | 201 (27.8) | 2161 (35.9) | 2083 (34.5) |
| Plus 2 BP medications | 275 (37.5) | 260 (36.0) | 1905 (31.6) | 1961 (32.4) |
| Plus 3 BP medications | 172 (23.5) | 162 (22.4) | 889 (14.8) | 928 (15.4) |
| Plus 4 BP medications | 36 (4.9) | 57 (7.9) | 238 (4.0) | 249 (4.1) |
| Other drugs used | ||||
| ACE inhibitor or ARB | 496 (67.7) | 509 (70.5) | 3857 (64.0) | 3887 (64.3) |
| Loop diuretic | 20 (2.7) | 26 (3.6) | 119 (2.0) | 146 (2.4) |
| SGLT2 inhibitor | 29 (4.0) | 34 (4.7) | 144 (2.4) | 140 (2.3) |
| MRAd | 118 (16.1) | 111 (15.4) | 722 (12.0) | 744 (12.3) |
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; CTD, chlorthalidone; eGFR, estimated glomerular filtration rate; HCTZ, hydrochlorothiazide; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NA, not applicable; SGLT2, sodium-glucose cotransport protein 2.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Included American Indian, Asian, Hawaiian, Pacific Islander, and multiracial.
c
Based on the Veterans Affairs urban, rural, or highly rural classification.
d
Included spironolactone and eplerenone.